Kyselina Zoledrónová Stada (Zoledronic Acid)

Zoledronic acid binds to hydroxyapatite at sites of active bone remodeling. Osteoclasts that attach to bone internalize the drug, which then inhibits farnesyl pyrophosphate synthase in the mevalonate pathway. This blocks prenylation of essential proteins, leading to reduced osteoclast activity, apoptosis, and ultimately decreased bone resorption.

The dose of zoledronic acid is individualized by the prescribing clinician based on the specific indication, patient renal function, and other clinical considerations. No fixed regimen is provided here; the prescriber determines the appropriate amount and frequency for each patient.

Safety data for zoledronic acid in pregnancy and lactation are limited. It is generally contraindicated unless the potential therapeutic benefit outweighs the risk to the fetus or infant. Women of child‑bearing potential should use effective contraception during treatment and for a period after the last dose.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and the necessary import documentation.

Zoledronic acid is a third‑generation, highly potent bisphosphonate that can be given once yearly or at other extended intervals, unlike older agents such as alendronate or risedronate that often require weekly or monthly dosing. Its greater potency may increase the risk of renal effects and osteonecrosis of the jaw, so monitoring is essential.

The product should be stored at ambient temperature, below 25 °C, in its original container. It must be protected from moisture and light, and should never be frozen or exposed to extreme temperatures. Proper storage helps maintain drug stability and efficacy.

Zoledronic acid is administered as an intravenous infusion, typically over 15 minutes, under medical supervision. The exact infusion rate, volume, and dilution are determined by the prescriber and pharmacy preparation guidelines to ensure safe delivery.

Serious adverse events include osteonecrosis of the jaw, atypical femoral fractures, severe renal impairment or acute renal failure, acute hypocalcemia, and severe hypersensitivity reactions such as anaphylaxis. Patients should be monitored for these conditions throughout therapy, and any signs should prompt immediate medical evaluation.

Zoledronic acid should be avoided in patients with severe renal impairment (creatinine clearance <30 mL/min), known hypersensitivity to the drug, active dental infections or recent invasive dental procedures, and in pregnant or breastfeeding women unless a compelling indication exists. Clinicians must assess individual risk before prescribing.